Orientations
RSV vaccine Post-Introduction Evaluation (rPIE) | Tools and materials
The RSV post-introduction evaluation (rPIE) is a tool that can be used to evaluate the impact of the maternal RSV vaccine and/or infant RSV maternal antibody (mAb) in a country where the RSV vaccine/mAb has been newly introduced. The objective of the rPIE is to identify challenges, recommend corrective actions, and understand best practices in RSV immunization program implementation.
The post-introduction evaluation (PIE) tools has been used for influenza, COVID-19 and routine childhood vaccines and provides a systematic method for evaluating the impact of the introduction of a vaccine on the existing immunization system in a country. WHO recommends that all countries that have introduced a new vaccine conduct a PIE.
The purpose of the rPIE tools is to provide a systematic method of performing the evaluation that is comparable across countries. The Pan American Health Organization (PAHO/WHO), in collaboration with CDC and the Task Force for Global Health (TFGH) has developed a series of tools and materials for implementing rPIE in countries that have recently introduced RSV immunization programs. The following tools and materials are attached:
- Concept note
- rPIE overview
- Pilot testing guidance
- Questionnaires and checklists
Langues
- Anglais
Année de publication
2026
Type
Orientations
Catégories
- Vaccins et dispositifs d'administration
Maladies
- RSV
Organisations
- Task Force for Global Health (TFGH)
- Centres de prévention et de contrôle des maladies (CDC)
- Organisation Mondiale de la Santé (OMS)
Mots-clés
- cPIE
Régions de l'OMS
- Région des Amériques
